Last reviewed · How we verify
Paroxetine; Paxil
At a glance
| Generic name | Paroxetine; Paxil |
|---|---|
| Also known as | Paroxetine, Paxil, Antidepressant |
| Sponsor | University of California, Los Angeles |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors (PHASE1, PHASE2)
- A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Electroacupuncture for Generalized Anxiety Disorder: Clinical Efficacy and Neuroimaging Mechanisms (NA)
- Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities (PHASE4)
- Transcutaneous Posterior Tibial Nerve Stimulation for Premature Ejaculation (NA)
- Effect of SC-ICBT for Adults With OCD：A Three-Arm Randomized Controlled Trial (NA)
- Building Ukraine's Strength in PTSD Treatment and Research (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paroxetine; Paxil CI brief — competitive landscape report
- Paroxetine; Paxil updates RSS · CI watch RSS
- University of California, Los Angeles portfolio CI